Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Panacea Biotec Limited
  6. News
  7. Summary
    531349   INE922B01023

PANACEA BIOTEC LIMITED

(531349)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Panacea Biotec : Russia signs deal with India to produce 100 million Sputnik V annual doses

04/05/2021 | 09:57am EDT

Moscow, Apr 5 (EFE).- The Russian Direct Investment Fund on Monday announced an agreement with the Indian Panacea Biotec to produce 100 million annual doses of the Sputnik V coronavirus vaccine.

The deal would allow RDIF to provide its international partners with the jab, the Russian sovereign fund said in a statement.

India is one of the first countries Russia has approached to manufacture the vaccine, approved by 59 countries.

"We are pleased to collaborate with RDIF to produce Sputnik V for global markets," Managing Director of Panacea Biotec Rajesh Jain said according to the statement.

"Panacea Biotec brings decades of vaccine manufacturing and distribution know-how to scale-up Sputnik V supplies. Panacea Biotec will produce Sputnik V in its internationally accredited facilities complying to strict GMP standards and prequalified by WHO," he added.

RDIF CEO Kirill Dmitriev said: "cooperation with Panacea Biotec is an important step to produce the vaccine in India and to supply our international partners around the world."

Last week, Dmitriev notified the Russian president Vladimir Putin that India and South Korea are producing the vaccine and that the RDIF has signed agreements with a dozen countries.

The overseas-manufactured doses can be administered to Russians as well as other countries' populations, Dmitriev added.

Russia is awaiting the arrival of a European Medicines Agency delegation which could conclude the vaccine approval process that started in early March. EFE

© 2021 EFE News Services (U.S.) Inc., source EFE Ingles

All news about PANACEA BIOTEC LIMITED
04/05PANACEA BIOTEC  : Ties Up With Russian Fund to Produce 100 Million Doses of COVI..
MT
04/05PANACEA BIOTEC  : Russia signs deal with India to produce 100 million Sputnik V ..
AQ
04/05PANACEA BIOTEC  : India's Panacea Biotec to produce 100 million Sputnik V doses ..
RE
2020PANACEA BIOTEC  : Biotech Subsidiary Encounters a Minor Fire Incident at Baddi F..
MT
2020PANACEA BIOTEC LIMITED : Spin off
FA
2020Indian drugmaker Biological E. to make substance used in J&J's potential COVI..
RE
More news
Financials
Sales 2020 5 441 M 74,3 M 74,3 M
Net income 2020 -1 943 M -26,5 M -26,5 M
Net Debt 2020 6 989 M 95,4 M 95,4 M
P/E ratio 2020 -3,45x
Yield 2020 -
Capitalization 23 306 M 318 M 318 M
EV / Sales 2019 4,04x
EV / Sales 2020 2,52x
Nbr of Employees 2 338
Free-Float 12,7%
Chart PANACEA BIOTEC LIMITED
Duration : Period :
Panacea Biotec Limited Technical Analysis Chart | 531349 | INE922B01023 | MarketScreener
Technical analysis trends PANACEA BIOTEC LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Rajesh Jain Managing Director & Executive Director
Sandeep Jain Joint Managing Director & Executive Director
Vinod Goel Group CFO, Secretary & Compliance Officer
Devender Gupta CFO & Head-Information Technology
Soshil Kumar Jain Chairman
Sector and Competitors